Division of Cancer Biology

Medicine & Life Sciences

1. Acoustics 12%
2. Adenoviridae 18%
3. Apoptosis 16%
4. Biomarkers 15%
5. Blood-Brain Barrier 13%
6. Bombesin 29%
7. bombesin (7-14) 13%
8. Bombesin Receptors 31%
9. Bone Marrow 20%
10. Bone Marrow Cells 8%
11. Boron Neutron Capture Therapy 9%
12. Bortezomib 24%
13. Brachytherapy 40%
14. Brain 16%
15. Breast 10%
16. Breast Neoplasms 36%
17. Carcinoma 14%
18. Cardiotoxicity 19%
19. Cell Line 9%
20. Cell-Free Nucleic Acids 11%
21. Chelating Agents 14%
22. Chemoradiotherapy 9%
23. Circulating Tumor DNA 32%
24. Copper-64 9%
25. Databases 10%
26. DNA 12%
27. DNA Damage 14%
28. DNA Repair 11%
29. DNA Replication 9%
30. Double-Stranded DNA Breaks 11%
31. Drug Resistance 17%
32. Drug Therapy 23%
33. Endometrial Neoplasms 11%
34. Endothelial Cells 9%
35. Fluorodeoxyglucose F18 15%
36. Gene Expression 11%
37. Gene Fusion 10%
38. Genes 29%
39. Glioblastoma 10%
40. Heart 13%
41. Heterografts 24%
42. human SSTR2 protein 17%
43. Hypoxia 11%
44. Immunotherapy 16%
45. In Vitro Techniques 23%
46. Ionizing Radiation 13%
47. Ligands 10%
48. Liquid Biopsy 14%
49. Lung 13%
50. Lung Neoplasms 9%
51. Magnetic Resonance Imaging 10%
52. Magnetic Resonance Spectroscopy 11%
53. Microbubbles 22%
54. MicroRNAs 45%
55. Molecular Imaging 14%
56. Multiple Myeloma 60%
57. Mutation 16%
58. Nanoparticles 10%
59. Neoplasm Metastasis 14%
60. Neoplasms 100%
61. Non-Small Cell Lung Carcinoma 15%
62. Ovarian Neoplasms 17%
63. Peptides 20%
64. Pharmaceutical Preparations 12%
65. Phosphorylation 8%
66. Phosphotransferases 8%
67. Platelet Endothelial Cell Adhesion Molecule-1 10%
68. plerixafor octahydrochloride 10%
69. Poly (ADP-Ribose) Polymerase-1 11%
70. Positron Emission Tomography Computed Tomography 10%
71. Positron-Emission Tomography 33%
72. Prostatic Neoplasms 28%
73. Proteasome Endopeptidase Complex 9%
74. Proteasome Inhibitors 10%
75. Proteins 16%
76. Radiation 61%
77. Radiation Oncologists 10%
78. Radiation Oncology 13%
79. Radioimmunotherapy 12%
80. Radioisotopes 8%
81. Radiopharmaceuticals 8%
82. Radiotherapy 83%
83. Recombinational DNA Repair 8%
84. Recurrence 17%
85. Residual Neoplasm 11%
86. RNA 11%
87. RNA Sequence Analysis 10%
88. somatostatin receptor 2 19%
89. Somatostatin Receptors 10%
90. Sonication 13%
91. Squamous Cell Carcinoma 10%
92. Survival 35%
93. T-Lymphocytes 13%
94. Telomere 10%
95. Theranostic Nanomedicine 8%
96. Therapeutics 40%
97. Tumor Microenvironment 11%
98. Untranslated RNA 9%
99. Uterine Cervical Neoplasms 71%
100. Waldenstrom Macroglobulinemia 44%